BIOMAT Database Logo BIOMAT Database Logo

Growth hormone therapy in normal short children induces a transitory decrease in plasma growth hormone releasing hormone levels and in human growth hormone responsiveness to exogenous growth hormone releasing hormone. 1992

I Gil-Ad, and B Klinger, and A Pertzelan, and B Erster, and A Silbergeld, and H Talpaz, and Z Laron
Institute of Pediatric and Adolescent Endocrinology, Beilinson Medical Center, Petah Tiqva, Israel.

A three-month study of the effect of growth hormone (hGH) therapy (0.1 U/kg/day sc) on plasma levels of GH releasing hormone (GHRH), somatostatin and insulin-like growth factor I (IGF-I) and on the hGH responsiveness to exogenous GHRH was carried out in 32 prepubertal short-stature children with normal GH secretion. Blood samples were collected prior to initiation of therapy, and at 5, 30 and 90 days of onset of therapy, as well as 2 and 90 days after termination of therapy. The nonconventional hGH therapy induced an increase in serum IGF-I levels which lasted as long as therapy was continued. Plasma GHRH levels showed an early transitory decrease after five days of therapy, whereas plasma somatostatin levels were unaltered. A slight suppression in hGH responsiveness to exogenous GHRH was found at 2 but not at 90 days after termination of hGH therapy. It is concluded that nonconventional hGH treatment does not cause permanent changes in physiological hGH secretion.

UI MeSH Term Description Entries
D007334 Insulin-Like Growth Factor I A well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on GROWTH HORMONE. It is believed to be mainly active in adults in contrast to INSULIN-LIKE GROWTH FACTOR II, which is a major fetal growth factor. IGF-I,Somatomedin C,IGF-1,IGF-I-SmC,Insulin Like Growth Factor I,Insulin-Like Somatomedin Peptide I,Insulin Like Somatomedin Peptide I
D007457 Iodine Radioisotopes Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes. Radioisotopes, Iodine
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D013004 Somatostatin A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal. Cyclic Somatostatin,Somatostatin-14,Somatotropin Release-Inhibiting Hormone,SRIH-14,Somatofalk,Somatostatin, Cyclic,Somatotropin Release-Inhibiting Factor,Stilamin,Somatostatin 14,Somatotropin Release Inhibiting Factor,Somatotropin Release Inhibiting Hormone
D013006 Growth Hormone A polypeptide that is secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Growth hormone, also known as somatotropin, stimulates mitosis, cell differentiation and cell growth. Species-specific growth hormones have been synthesized. Growth Hormone, Recombinant,Pituitary Growth Hormone,Recombinant Growth Hormone,Somatotropin,Somatotropin, Recombinant,Growth Hormone, Pituitary,Growth Hormones Pituitary, Recombinant,Pituitary Growth Hormones, Recombinant,Recombinant Growth Hormones,Recombinant Pituitary Growth Hormones,Recombinant Somatotropins,Somatotropins, Recombinant,Growth Hormones, Recombinant,Recombinant Somatotropin
D013007 Growth Hormone-Releasing Hormone A peptide of 44 amino acids in most species that stimulates the release and synthesis of GROWTH HORMONE. GHRF (or GRF) is synthesized by neurons in the ARCUATE NUCLEUS of the HYPOTHALAMUS. After being released into the pituitary portal circulation, GHRF stimulates GH release by the SOMATOTROPHS in the PITUITARY GLAND. Growth Hormone-Releasing Factor,Somatocrinin,Somatotropin-Releasing Factor 44,Somatotropin-Releasing Hormone,GHRH 1-44,GRF 1-44,Growth Hormone-Releasing Factor 44,Human Pancreatic Growth Hormone-Releasing Factor,Somatoliberin,hpGRF 44,Growth Hormone Releasing Factor,Growth Hormone Releasing Factor 44,Growth Hormone Releasing Hormone,Somatotropin Releasing Factor 44,Somatotropin Releasing Hormone

Related Publications

I Gil-Ad, and B Klinger, and A Pertzelan, and B Erster, and A Silbergeld, and H Talpaz, and Z Laron
Plasma growth hormone responses to growth hormone-releasing hormone in children of short stature.
August 1989, Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association,
I Gil-Ad, and B Klinger, and A Pertzelan, and B Erster, and A Silbergeld, and H Talpaz, and Z Laron
Peripheral plasma levels of human growth hormone releasing hormone (GHRH) during the sleep test in short children.
April 1998, Endocrine journal,
I Gil-Ad, and B Klinger, and A Pertzelan, and B Erster, and A Silbergeld, and H Talpaz, and Z Laron
Short-term growth hormone therapy increases serum lipoprotein (a) levels in normal short children without growth hormone deficiency.
July 1996, Hormone research,
I Gil-Ad, and B Klinger, and A Pertzelan, and B Erster, and A Silbergeld, and H Talpaz, and Z Laron
Effect of growth hormone-releasing factor on plasma growth hormone, prolactin and somatomedin C in hypopituitary and short normal children.
January 1985, Hormone research,
I Gil-Ad, and B Klinger, and A Pertzelan, and B Erster, and A Silbergeld, and H Talpaz, and Z Laron
Evaluation of the growth-hormone-releasing hormone test in short normal and growth-hormone-deficient children.
January 1990, Hormone research,
I Gil-Ad, and B Klinger, and A Pertzelan, and B Erster, and A Silbergeld, and H Talpaz, and Z Laron
Circulating immunoreactive growth hormone releasing hormone concentrations and growth hormone response to growth hormone releasing hormone in short children.
December 1993, European journal of pediatrics,
I Gil-Ad, and B Klinger, and A Pertzelan, and B Erster, and A Silbergeld, and H Talpaz, and Z Laron
Increase of serum lipoprotein (a) levels during growth hormone therapy in normal short children.
January 1998, European journal of pediatrics,
I Gil-Ad, and B Klinger, and A Pertzelan, and B Erster, and A Silbergeld, and H Talpaz, and Z Laron
Human growth hormone and gonadotropin releasing hormone analog combination therapy increases predicted height in short normal girls.
January 2003, Clinical pediatrics,
I Gil-Ad, and B Klinger, and A Pertzelan, and B Erster, and A Silbergeld, and H Talpaz, and Z Laron
Plasma levels of exogenous thyrotropin-releasing hormone (TRH) in normal subjects: relationship to endocrine and behavioral effects.
November 1985, Pharmacopsychiatry,
I Gil-Ad, and B Klinger, and A Pertzelan, and B Erster, and A Silbergeld, and H Talpaz, and Z Laron
Plasma somatotropin response to exogenous growth hormone releasing factor in lambs.
April 1987, Journal of animal science,
Copied contents to your clipboard!